• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Seven Tumor Types: Pros and Cons


Unlike the Oncology Care Model, the Enhancing Oncology Model will focus on 7 common cancer types, which experts say offers advantages and disadvantages for practices.

Moderator Stuart Staggs, MSIE, senior director, strategic programs, The US Oncology Network, led a discussion on a pros and cons of limiting the Enhancing Oncology Model (EOM) to 7 common cancer types. Stephen Schleicher, MD, MBA, chief medical officer, Tennessee Oncology, and Fred Divers, MD, chief medical officer, American Oncology Network and medical oncologist, Genesis Cancer and Blood Institute of Arkansas, agreed that honing in common cancers could lead to better predictability in cost of care. Kashyap Patel, MD, CEO, Carolina Blood and Cancer Care Associates and president, Community Oncology Alliance, raised concerns that lack of monthly payments for other cancer types for harm practices giving patients supportive services; Divers and Schleicher concurred on the potential effects on quality.

Related Videos
Douglas K. Marks, MD | Image credit: NYU Langone Health
Carrie Kozlowski
Kiana Mehring, MBA, director of strategic partnerships, managed care at Florida Cancer Specialists & Research Institute (FCS)
Sudipto Mukherjee, MD, PhD, MPH, hematology and medical oncology, Cleveland Clinic
Video 12 - "Cost-Effective Medication Access in Demodex Blepharitis Management"
Video 10 - "Patient Education Drives BTK Inhibitor Treatment Adherence"
Related Content
© 2024 MJH Life Sciences
All rights reserved.